NCT05847413View on ClinicalTrials.gov

Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 30, 2020

Primary Completion Date

December 10, 2021

Study Completion Date

December 10, 2021

Conditions
Type 1 Diabetes
Interventions
DRUG

Verapamil

Subjects will receive oral verapamil for 12 weeks

Trial Locations (1)

98101

Benaroya Research Institute, Seattle

Sponsors
All Listed Sponsors
lead

Benaroya Research Institute

OTHER